** Shares of Arovella Therapeutics rise as much as 15.7% to A$0.203, their biggest intraday pct gain since Oct 11, 2024
** The biotech firm says it secured A$20 mln ($12.39 mln) placement funding to wrap up inaugural clinical trial of lymphoma, leukemia drug ALA-101
** Placement is at an issue price of A$0.17 per share, representing a 2.9% discount to last trade
** Stock hits its highest level since mid-November 2024
** Over 4.5 mln shares change hands, 5.3x the 30-day avg
** Stock rose 47.8% in 2024
($1 = 1.6139 Australian dollars)
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.